Following yesterday's announcement by the Department of Health of a new £816 million investment in health research, the Association of the British Pharmaceutical Industry (ABPI) have welcomed the record amount as a signal of Government's commitment to invest in innovation.
The ABPI have also used this announcement to set out that in any new industrial strategy for UK, the opportunity must be seized for the NHS to be a real engine for innovation and growth, and be the best place globally for pharmaceutical companies to research and launch new medicines.
Dr Jacintha Sivarajah, Head of Medical Affairs at the ABPI said:
“This investment in the future of UK biomedical science is a signal that this Government understands the value of investing in innovation.
The UK is already a world leader in pioneering medical breakthroughs and the pharmaceutical industry in the UK is committed to working with policymakers to ensure that this strong tradition continues.
It is estimated that for every £1 the Department of Health invests, hospitals and universities will generate £6 from public funders of research, charities and industry partners.
Looking forward to the Government’s new industrial strategy, we must make sure that the NHS is the best place globally for companies to research and launch new medicines.
Pharmaceutical companies working alongside our health ecosystem of world class universities, scientists and clinicians can be a real engine for innovation and growth, delivering tangible benefits for patients and the UK economy.”
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.